Several studies have demonstrated that patients with cancer as well as experimental animals with transplanted tumours show a decrease in delayed-type hypersensitivity (DTH) reactions and experience cutaneous anergy (Stein et al., 1976; Broder and Waldmann, 1978; Giuliano et al., 1979) . This fact was attributed to an induction of suppressor cells (Kirchner, 1978; Yu et al., 1977; North and Bursuker, 1984) , the emergence of soluble suppressive factors (Whittaker et al., 1971; Nimberg et alt, 1975; North et alt, 1984) or to a lack of lymphokines (Fearon et alt, 1990 ) associated with the development of neoplasms. Consequently, impressive results were achieved by the induction of lytic effector T-cell function by interleukin 2 (IL-2), leading to the establishment of lymphokine-activated killer cell therapy in patients with various malignancies.
Established prognostic markers in breast cancer include mainly tumour-associated characteristics such as the number of involved axillary lymph nodes, tumour size, oestrogen receptor status and oncogene overexpression (Clark and McGuire, 1988; Contesso et al., 1989) , but no immunological characteristics of tumour or host. A series of studies have been performed to investigate the latter aspect (Penn, 1982 (Penn, . 1988 Zielinski et al.. 1989a; Knogler et al., 1992) . The majority of these studies have dealt, however, with certain functions of the immune system assessed at single time points during the course of the disease and are thus of limited value, as both, chemo-and radiotherapy can exert considerable influence upon the parameters measured (Whittaker et al.. 1971; Stein et al.. 1976 ; Vose and Moore. 1980 : Uchida and Hoshino, 1980; Cunningham-Rundles et al., 1981; White et al., 1982; Tichatschek et alt, 1988 EBCTCG, 1992) In order to analyse the influence of sera of patients with breast cancer upon lymphocyte proliferation, PBMCs derived from healthy individuals were preincubated with sera diluted 1:10 or 1:100 (v/v), respectively, at 3TC for 3 h and submitted subsequently to PHA assays as above.
Characterisation of suppressive factors in sera Sera were obtained from (i) six healthy controls and (ii) from nine patients with metastatic breast cancer following surgery. Sera were diluted 1:2 in phosphate-buffered saline and subjected to ultrafiltration through Amicon CF 25 Centriflow cones (Amicon, Danvers, MA, USA) for 15 min at 800 g (mol. wt cut-off point 25 kDa) at room temperature. PBMCs were isolated as described previously and resuspended to a concentration of I x 10' lymphocytes per ml of supplemented When patients who received adjuvant CMF treatment were studied further for the proliferative rate of their PBMCs in response to PHA, the decrease seen after 6 months had vanished after an additional 6 months (Figure 1) In a further analysis, the course of proliferation of PBMCs in response to PHA before the initiation of treatment and after 12 months was analysed prospectively and put into context with disease status after a total of 36 months.
Twelve months after surgery, 82 patients had remained without evidence of disease, as assessed by clinical means. Of these patients, 15 showed progressive disease after 36 months, whereas 67 patients had remained disease free. Owing to a great variability between the patients, the absolute mitogenic stimulation of PBMCs assessed neither preoperatively nor after 12 months showed significant prognostic relevance. Nevertheless, when the change in lymphocyte proliferation after this mitogenic stimulation was compared with the clinical outcome after 3 years, a significant correlation was seen. Patients who were to remain in complete remission for 36 months showed an increase in the proliferative responses of their PBMCs in response to PHA after 12 months of 15.9 ± 24.7%, whereas patients with future progressive disease showed a further decline from their initial level of proliferation by 26.5 ± 14.1% (P<0.001). This pattern was found in patients with various initial stages of breast cancer (Table III) Influence ofpatients' sera upon PBMC proliferation In order to evaluate the possibility of a soluble factor secreted by the tumour or other soluble factors present in the sera of patients with metastatic breast cancer, PBMC proliferation assays were performed in the presence of sera derived from patients with untreated metastatic breast cancer. Although there was a tendency in data from which one could suspect a suppressive influence of the diluting agent itself, there was no significant difference between PHA stimulation of PBMCs with or without control sera in different dilutions. In contrast, sera derived from patients with untreated metastatic breast cancer in contrast significantly inhibited the proliferation of control PBMCs in a dilution-dependent manner (serum dilution 1:10, P <0.001; 1:100, P> 0.1). Table IV shows the results of two representative experiments out of the performed six assays. Table V shows the successful enrichment by ultracentrifugation of the factor(s) responsible for the suppression of PBMC proliferation in the protein fraction below 25 kDa. This serum preparation resulted in the most effective suppression of PHA stimulation which could not be reversed by dilution (Table  V) . (Whittaker et al., 1971; Stein et al., 1976) . Our data demonstrated, finally that, irrespective of the kind of adjuvant treatment, two-thirds of patients whose PBMCs showed a drop in their PHA-induced proliferation within 1 year experienced rapid recurrence of disease. This fact was fiuther corroborated by the observation that breast cancer did not recur within the observation period in patients whose PBMCs showed an increase in PHA-induced proliferation.
Tlhe results presented in the current report pose a series of questions. Thus, the persistent decrease in PHA-induced proliferation of PBMCs derived from patients with breast cancer has to be explained. Considering our data there could be several reasons for this finding. The initial decrease in lymphocyte proliferation could be due to the presence of the tumour and its influence upon the immune system. Such assumptions can be made on the basis of data obtained in humans with cancer as well as in experimental animals which demonstrated decreased DTH and a defect in lymphocyte proliferation in the presence of neoplastic tissue (Stein et al., 1976; Broder et al., 1978; Giuliano et al., 1979) . Several reasons have been discussed for these findings, including defective lymphokine production and an increase in the production of suppressor factors by the tumour (Whittaker et al., 1971; Nimberg et al., 1975; North et al., 1984; Mizoguchi et al., 1992) .
Previous studies by other investigators (Whittaker et al., 1971; Nimberg et al., 1975; Giuliano et al., 1979; North et al., 1984; Mizoguchi et al., 1992) (Yu et al., 1977; North et al., 1984) or an alteration in signal transduction moleules (Mizoguchi et al., 1992) , must be considered.
The problem could be further aggravated by the fact that adjuvant cytostatic treatment with CMF has previously been demonstrated in studies in this laboratory to lead to a prolonged defect in the production of a primary immune response following vaccination (Zielinski et al., 1986) and lymphocyte proliferation (Knogler et al., 1992) as well as lymphokine production (Zielinski et al., 1986 (Zielinski et al., , 1989b . The latter aspects also constitute the most likely explanations for the decrease in PHA-induced lymphocyte proliferation under immediate CMF therapy seen in the present study.
Clinically, the decrease in lymphocyte proliferation in twothirds of patients who were to develop metastases within the relatively near future ckarly constitutes a new prognostic tool for the prediction of the development of early metastatic disease. Neverthekss, owing to the relatively small number of patients and short follow-up times, the ultimate prognostic value of this phenomenon has to be proven in a largr study, which is ongoing in our institute. Although previous studie on a similar question have failed to find such a prognostic value for PHA stimulation (Stein et al., 1976; Nordman et al., 1985) in solid tumours, it is an accepted predictive parameter in Hodgkin's disease (Bj6rkholm et al., 1982; Wedelin et al., 1982) . However, the lack of such a finding in patients with solid tumours may be due to the heterogeneity of studied patients so far. Nevertheless, the fact is surprisng, as immunological variables have not been used until now as either prognostic tools or for the design of adjuvant trials. However, several studies have demonstrated a clear assocation of lytic effector lymphocyte function and such established prognostic variables as tumour load (Contesso et al., 1989) , oestrogen receptor status (Clark et al., 1988) and amplification of the HER-2neu oncogene (Zeillinger et al., 1989 
